Editas Medicine Statistics
Total Valuation
Editas Medicine has a market cap or net worth of $391.33 million. The enterprise value is $288.05 million.
| Market Cap | 391.33M |
| Enterprise Value | 288.05M |
Important Dates
The last earnings date was Tuesday, May 5, 2026, before market open.
| Earnings Date | May 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Editas Medicine has 153.46 million shares outstanding. The number of shares has increased by 11.90% in one year.
| Current Share Class | 153.46M |
| Shares Outstanding | 153.46M |
| Shares Change (YoY) | +11.90% |
| Shares Change (QoQ) | +0.64% |
| Owned by Insiders (%) | 0.20% |
| Owned by Institutions (%) | 34.37% |
| Float | 124.27M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.19 |
| Forward PS | 27.68 |
| PB Ratio | 52.42 |
| P/TBV Ratio | 89.47 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.44 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.22, with a Debt / Equity ratio of 3.92.
| Current Ratio | 3.22 |
| Quick Ratio | 3.17 |
| Debt / Equity | 3.92 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -17.71 |
Financial Efficiency
Return on equity (ROE) is -326.07% and return on invested capital (ROIC) is -96.55%.
| Return on Equity (ROE) | -326.07% |
| Return on Assets (ROA) | -26.95% |
| Return on Invested Capital (ROIC) | -96.55% |
| Return on Capital Employed (ROCE) | -81.26% |
| Weighted Average Cost of Capital (WACC) | 16.10% |
| Revenue Per Employee | $444,747 |
| Profits Per Employee | -$1.25M |
| Employee Count | 87 |
| Asset Turnover | 0.19 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +18.75% in the last 52 weeks. The beta is 2.10, so Editas Medicine's price volatility has been higher than the market average.
| Beta (5Y) | 2.10 |
| 52-Week Price Change | +18.75% |
| 50-Day Moving Average | 2.95 |
| 200-Day Moving Average | 2.66 |
| Relative Strength Index (RSI) | 44.56 |
| Average Volume (20 Days) | 3,536,834 |
Short Selling Information
The latest short interest is 15.07 million, so 9.82% of the outstanding shares have been sold short.
| Short Interest | 15.07M |
| Short Previous Month | 9.56M |
| Short % of Shares Out | 9.82% |
| Short % of Float | 12.12% |
| Short Ratio (days to cover) | 5.96 |
Income Statement
In the last 12 months, Editas Medicine had revenue of $38.69 million and -$108.95 million in losses. Loss per share was -$1.18.
| Revenue | 38.69M |
| Gross Profit | -42.27M |
| Operating Income | -89.03M |
| Pretax Income | -108.95M |
| Net Income | -108.95M |
| EBITDA | -85.19M |
| EBIT | -89.03M |
| Loss Per Share | -$1.18 |
Balance Sheet
The company has $123.65 million in cash and $17.30 million in debt, with a net cash position of $106.35 million or $0.69 per share.
| Cash & Cash Equivalents | 123.65M |
| Total Debt | 17.30M |
| Net Cash | 106.35M |
| Net Cash Per Share | $0.69 |
| Equity (Book Value) | 4.41M |
| Book Value Per Share | 0.05 |
| Working Capital | 88.29M |
Cash Flow
In the last 12 months, operating cash flow was -$140.50 million and capital expenditures -$585,000, giving a free cash flow of -$141.09 million.
| Operating Cash Flow | -140.50M |
| Capital Expenditures | -585,000 |
| Depreciation & Amortization | 3.84M |
| Net Borrowing | n/a |
| Free Cash Flow | -141.09M |
| FCF Per Share | -$0.92 |
Margins
Gross margin is -109.24%, with operating and profit margins of -230.09% and -281.59%.
| Gross Margin | -109.24% |
| Operating Margin | -230.09% |
| Pretax Margin | -281.59% |
| Profit Margin | -281.59% |
| EBITDA Margin | -220.16% |
| EBIT Margin | -230.09% |
| FCF Margin | n/a |
Dividends & Yields
Editas Medicine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.90% |
| Shareholder Yield | -11.90% |
| Earnings Yield | -27.63% |
| FCF Yield | -35.77% |
Analyst Forecast
The average price target for Editas Medicine is $5.78, which is 126.67% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.78 |
| Price Target Difference | 126.67% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | -40.25% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Editas Medicine has an Altman Z-Score of -15.61 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -15.61 |
| Piotroski F-Score | 3 |